News from Zyme and the companies we work with.
Metrion Biosciences strengthens team with three key appointments
Clare Rutty promoted to CFO, Sue Peffer appointed Head of Marketing, Leanne Clarke appointed HR Officer Cambridge, UK, 11 March 2024: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract [...]
Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics
Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics Dundee, UK, 11 March 2024: Ubiquigent Limited [...]
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications Data generated fully support continued clinical development of EXN407 [...]
SolasCure Publishes Phase IIa Clinical Trial Report in Leading Wound Care Journal
Publication in the ‘International Wound Journal’ provides robust validation of the Phase IIa trial data that will enable further clinical studies Study demonstrates proof-of-concept and strong safety profile of Aurase [...]
Bio-Rad Launches Vericheck ddPCR Replication Competent Lentivirus and Replication Competent AAV Kits for Cell and Gene Therapy Production
Rapid, Sensitive, and Validated Detection of Viral Replication Genes Using Droplet Digital™ PCR During Cell and Gene Therapy Production HERCULES, Calif. — February 27, 2024 — Bio-Rad Laboratories, Inc. (NYSE: [...]
Optibrium Launches a Metabolism Prediction Software Platform Tailored to DMPK Scientists
Semeta™ offers high sensitivity and superior precision for the prediction of Phase I and II metabolic routes, sites, products and liabilities in early drug discovery CAMBRIDGE, UK, 27 February 2024 [...]
MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space
Company’s synthetic affinity reagents are antibody alternatives designed to advance the speed, safety, and efficiency of manufacturing at scale, making advanced therapies more accessible to patients. Investment led by Mercia [...]
Optibrium enables collaborative design in its StarDrop platform
The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking The software promotes collaboration within and across teams [...]
Closed Loop Medicine demonstrates application of novel drug plus software product for personalized treatment of hypertension
Study published in JAHA validates use of proprietary technology to identify personalized dose regimen, leading to improved blood pressure control and exceptionally high adherence in hypertension patients Findings will guide [...]
Yokogawa introduces CellVoyager High-Content Analysis System CQ3000
New system enables advanced analysis of live cell cultures with high-definition, high-speed 3D imaging Expands Yokogawa’s CellVoyager range, comprising its imaging devices and analysis software, to support research applications from [...]
Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer
Appointment forms part of ongoing plans for continued development of the GenLink3D genomics platform and formation of strategic commercial and academic partnerships Cambridge, UK, 31 January 2024: Enhanc3D Genomics, a [...]
CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market
Cambridge, UK, 30 January 2024: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the appointment of Joseph Parisi as [...]